Search research articles
Contact Us
Filters
Showing results (81-90 of 88) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 88 results.
Journal of Medicinal Chemistry
|
July 13, 2021
Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors
Jonathan T Seal, Stephen J Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry
|
August 13, 2021
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression
Katherine L Jones, Dominic M Beaumont, Sharon G Bernard, et al.
Cancer Discovery
|
September 2, 2022
Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia
Yiman Liu, Qinglan Li, Fatemeh Alikarami, et al.
Cancer Research
|
November 11, 2015
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
Sarah Picaud, Oleg Fedorov, Angeliki Thanasopoulou, et al.
Science (New York, N.Y.)
|
March 21, 2020
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
Omer Gilan, Inmaculada Rioja, Kathy Knezevic, et al.
Journal of Medicinal Chemistry
|
January 7, 2022
Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate
Philip G Humphreys, Stephen J Atkinson, Paul Bamborough, et al.
The Lancet. Gastroenterology & Hepatology
|
July 19, 2018
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score
Marco Carbone, Alessandra Nardi, Steve Flack, et al.
Journal of Medicinal Chemistry
|
June 12, 2024
Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787
David J Hirst, Paul Bamborough, Niam Al-Mahdi, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 88) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 88 results.
Journal of Medicinal Chemistry
|
July 13, 2021
Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors
Jonathan T Seal, Stephen J Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry
|
August 13, 2021
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression
Katherine L Jones, Dominic M Beaumont, Sharon G Bernard, et al.
Cancer Discovery
|
September 2, 2022
Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia
Yiman Liu, Qinglan Li, Fatemeh Alikarami, et al.
Cancer Research
|
November 11, 2015
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
Sarah Picaud, Oleg Fedorov, Angeliki Thanasopoulou, et al.
Science (New York, N.Y.)
|
March 21, 2020
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
Omer Gilan, Inmaculada Rioja, Kathy Knezevic, et al.
Journal of Medicinal Chemistry
|
January 7, 2022
Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate
Philip G Humphreys, Stephen J Atkinson, Paul Bamborough, et al.
The Lancet. Gastroenterology & Hepatology
|
July 19, 2018
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score
Marco Carbone, Alessandra Nardi, Steve Flack, et al.
Journal of Medicinal Chemistry
|
June 12, 2024
Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787
David J Hirst, Paul Bamborough, Niam Al-Mahdi, et al.
Page
of 9